- Home
- HYPR vs SPRO Comparison
HYPR vs SPRO Comparison
Compare HYPR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- SPRO
- Stock Information
- Founded
- HYPR 2014
- SPRO 2013
- Country
- HYPR United States
- SPRO United States
- Employees
- HYPR N/A
- SPRO N/A
- Industry
- HYPR Medical Specialities
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- HYPR Health Care
- SPRO Health Care
- Exchange
- HYPR Nasdaq
- SPRO Nasdaq
- Market Cap
- HYPR 71.9M
- SPRO 62.7M
- IPO Year
- HYPR N/A
- SPRO 2017
- Fundamental
- Price
- HYPR $1.02
- SPRO $1.17
- Analyst Decision
- HYPR Hold
- SPRO Buy
- Analyst Count
- HYPR 2
- SPRO 3
- Target Price
- HYPR $1.43
- SPRO $5.00
- AVG Volume (30 Days)
- HYPR 126.2K
- SPRO 470.6K
- Earning Date
- HYPR 11-12-2024
- SPRO 11-14-2024
- Dividend Yield
- HYPR N/A
- SPRO N/A
- EPS Growth
- HYPR N/A
- SPRO N/A
- EPS
- HYPR N/A
- SPRO 0.06
- Revenue
- HYPR $13,255,000.00
- SPRO $106,455,000.00
- Revenue This Year
- HYPR $31.69
- SPRO N/A
- Revenue Next Year
- HYPR $33.96
- SPRO N/A
- P/E Ratio
- HYPR N/A
- SPRO $17.92
- Revenue Growth
- HYPR 35.67
- SPRO 37.01
- 52 Week Low
- HYPR $0.76
- SPRO $1.01
- 52 Week High
- HYPR $1.42
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- HYPR 59.88
- SPRO 41.49
- Support Level
- HYPR $0.82
- SPRO $1.28
- Resistance Level
- HYPR $0.98
- SPRO $1.22
- Average True Range (ATR)
- HYPR 0.06
- SPRO 0.07
- MACD
- HYPR 0.01
- SPRO -0.01
- Stochastic Oscillator
- HYPR 91.45
- SPRO 32.73
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its sales from the following sources: 1) device sales which consist of sales of MRI devices and 2) service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.